Revvity Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.9B+5.7% YoYTTM through 5 Jul 2026
Net Income $237.6M-12.1% YoYTTM through 5 Jul 2026
Free Cash Flow $558.1MTTM through 5 Jul 2026
Margins
| Current | |
|---|---|
| Gross Margin | 54.8% |
| EBITDA Margin | 26.5% |
| Operating Margin | 12.5% |
| Net Margin | 8.2% |
Returns
3.3%ROE
2.0%ROA
2.5%ROIC
Balance Sheet Health
Debt / Equity0.44x
Current Ratio1.68x
Net Debt$2.3B
Cash & Equivalents$1B
Quality Metrics
Altman Z-Score3.15
Piotroski F-Score7 / 9
FCF Margin19.2%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $2.9B
Diluted EPS$2.08TTMFY2025: $2.07
Dividend
$0.21Per share, FY20260.15%Yield-5.6%5-yr growth
Capital Allocation
R&D Spend$215.8M
Capex Intensity2.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Life Sciences | $1.4B | +2.3% | |
| Diagnostics | $1.4B | +5.1% | View detailsThe company announced its strategic decision to divest its Immunodiagnostics business in China, which represented approximately 6% of total revenue in fiscal year 2025. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.